InflaRx (NASDAQ:IFRX) Shares Up 1.3%

InflaRx (NASDAQ:IFRX) shares shot up 1.3% during mid-day trading on Tuesday . The company traded as high as $1.65 and last traded at $1.61. 57,793 shares changed hands during trading, a decline of 67% from the average session volume of 176,121 shares. The stock had previously closed at $1.59.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of InflaRx in a report on Monday, June 24th.

InflaRx Price Performance

The stock has a market cap of $94.80 million, a price-to-earnings ratio of -2.06 and a beta of 1.58. The firm’s fifty day moving average price is $1.54 and its two-hundred day moving average price is $1.52.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). InflaRx had a negative net margin of 44,046.09% and a negative return on equity of 47.03%. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.04 million. On average, equities research analysts anticipate that InflaRx will post -0.98 earnings per share for the current year.

Institutional Trading of InflaRx

A hedge fund recently raised its stake in InflaRx stock. Ikarian Capital LLC grew its position in shares of InflaRx (NASDAQ:IFRX) by 2.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 704,987 shares of the company’s stock after buying an additional 16,383 shares during the quarter. Ikarian Capital LLC owned 1.20% of InflaRx worth $1,086,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.